News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IMPAX Laboratories, Inc. (IPXL) Files Motion To Intervene As Defendant In Litigation Related To Generic Allegra-D


10/19/2005 5:12:52 PM

HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 28, 2005--IMPAX Laboratories, Inc. (NASDAQ:IPXL) today announced that it has filed a motion in the United States District Court for the District of Columbia to intervene as a defendant in a lawsuit by Barr Laboratories, Inc. against the United States Food and Drug Administration (FDA). Earlier this month, Barr Laboratories, a subsidiary of Barr Pharmaceuticals, Inc. (NYSE:BRL), brought suit against the FDA in an attempt to prevent the agency from granting final approval to IMPAX's Abbreviated New Drug Application (ANDA) for its Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets, a generic version of Allegra-D(R). IMPAX was granted tentative approval of the generic product in February 2004. Aventis Pharmaceuticals markets Allegra-D for the treatment of the symptoms associated with seasonal allergic rhinitis. According to NDCHealth, U.S. sales of Allegra-D were approximately $425 million in the 12 months ended December 31, 2004.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES